(4S)-4-(3,4-DICHLOROPHENYL)-7-((1,2,4)TRIAZOLO(1,5-A)PYRIDIN-6-YL)-1,2,3,4-TETRAHYDROISOQUINOLINE
Major Depression
Bristol-Myers SquibbSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
235 Active assets in the Major Depression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Risperdal Johns Hopkins University | Phase 4 | BBB |
Zelapar Corium Innovations, Inc. | Phase 4 | BBB |
S-Ketamine Janssen Research & Development, LLC | Phase 4 | BBB |
EDIVOXETINE Eli Lilly and Company | Phase 3 | BBB |
Opc-34712 Nova Scotia Health Authority | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →